Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-312025-01-01falseProvision of sales and development services for its parent810truetruefalse 09306017 2025-01-01 2025-12-31 09306017 2024-01-01 2024-12-31 09306017 2025-12-31 09306017 2024-12-31 09306017 c:Director2 2025-01-01 2025-12-31 09306017 d:ComputerEquipment 2025-01-01 2025-12-31 09306017 d:ComputerEquipment 2025-12-31 09306017 d:ComputerEquipment 2024-12-31 09306017 d:CurrentFinancialInstruments 2025-12-31 09306017 d:CurrentFinancialInstruments 2024-12-31 09306017 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 09306017 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 09306017 d:ShareCapital 2025-12-31 09306017 d:ShareCapital 2024-12-31 09306017 d:RetainedEarningsAccumulatedLosses 2025-12-31 09306017 d:RetainedEarningsAccumulatedLosses 2024-12-31 09306017 c:FRS102 2025-01-01 2025-12-31 09306017 c:Audited 2025-01-01 2025-12-31 09306017 c:FullAccounts 2025-01-01 2025-12-31 09306017 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 09306017 c:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 09306017 2 2025-01-01 2025-12-31 09306017 e:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure

Registered number: 09306017









PULMONX UK LIMITED









FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025

 
PULMONX UK LIMITED
REGISTERED NUMBER: 09306017

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 5 
428,069
363,428

Cash at bank and in hand
 6 
379,242
402,177

  
807,311
765,605

Creditors: amounts falling due within one year
 7 
(386,757)
(393,113)

Net current assets
  
 
 
420,554
 
 
372,492

Total assets less current liabilities
  
420,554
372,492

  

Net assets
  
420,554
372,492


Capital and reserves
  

Called up share capital 
  
1,000
1,000

Profit and loss account
  
419,554
371,492

  
420,554
372,492


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


J Erath
Director

Date: 10 September 2026

The notes on pages 2 to 7 form part of these financial statements.

Page 1

 
PULMONX UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.


General information

Pulmonx UK Limited (the Company) is a company incorporated in the United Kingdom under the Companies Act.

The Company is a private company limited by shares, incorporated in England and Wales. The registered office is Suite 4, 7th Floor, 50 Broadway, London, United Kingdom, SW1H 0DB. 

The principal activity of the Company in the year under review was that of the provision of sales and development services for its parent.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The ultimate parent of the Company, Pulmonx Corporation, a NASDAQ listed company, remains financially strong. Pulmonx Corporation has sufficient cash, cash equivalents and marketable securities to continue for a period longer than 12 months from the date of the issuance of the financial statements. A review of the ultimate parent company’s financial information as at 31 December 2025 and post year end has been undertaken and it has been determined that they have sufficient financial resources to support the UK entity as required and as the ultimate parent company in the group. 
 
Besides the directors of Pulmonx International Sarl, the immediate parent company, have signed a letter of support have provided a commitment to provide any financial support which may be necessary in order that the Company can meet its liabilities, as they fall due, for a period of at least 12 months from the signing of the balance sheet. As a result of this commitment the directors have continued to adopt the going concern basis in preparing these financial statements.

Page 2

 
PULMONX UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.3

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP and balances are rounded to the nearest whole pound.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Profit and Loss Account within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

 
2.4

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Turnover represents amounts charged to the Company's parent under a transfer pricing agreement for development services provided, excluding value added tax. Turnover is recognised when chargeable costs are incurred.

 
2.5

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.6

Pensions

Defined contribution pension plan

The Company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Page 3

 
PULMONX UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.7

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the .

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
∙The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
∙Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.8

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment
-
Over 3 years

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.9

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 4

 
PULMONX UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

2.Accounting policies (continued)

 
2.10

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.11

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 8 (2024 - 10).


4.


Tangible fixed assets


Computer equipment

£



Cost or valuation


At 1 January 2025
1,435



At 31 December 2025

1,435



Depreciation


At 1 January 2025
1,435



At 31 December 2025

1,435



Net book value



At 31 December 2025
-



At 31 December 2024
-

Page 5

 
PULMONX UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5.


Debtors

2025
2024
£
£


Amounts owed by group undertakings
381,929
313,169

Other debtors
7,101
3,030

Prepayments and accrued income
34,699
26,305

Deferred taxation
4,340
20,924

428,069
363,428



6.


Cash and cash equivalents

2025
2024
£
£

Cash at bank and in hand
379,242
402,177



7.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
300
6,810

Corporation tax
74,219
25,485

Other taxation and social security
43,957
58,690

Other creditors
8,784
7,102

Accruals
259,497
295,026

386,757
393,113



8.


Pension commitments

The Company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Company  in an independently administered fund. The pension cost charge represents contributions payable by the Company  to the fund and amounted to £27,146 (2024 - £21,582). Contributions totalling £5,532 (2024 - £4,393) were payable to the fund at the balance sheet date and are included in creditors.

Page 6

 
PULMONX UK LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

9.


Controlling party

Pulmonx Corporation (incorporated in United States of America) is regarded by the directors as being the company's ultimate parent company.

The immediate parent entity is Pulmonx International Sarl, a company registered in Switzerland and which is a 100% subsidiary of Pulmonx Corporation. The largest and smallest group undertakings for which group accounts have been prepared is that headed by Pulmonx Corporation, a NASDAQ listed company registered in the United States of America. The address of Pulmonx Corporation is 700 Chesapeake Drive, Redwood City, CA 94063, USA.


10.


Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2025 was unqualified.

The audit report was signed on 10 September 2026 by Simon Buss (Senior Statutory Auditor) on behalf of Nortons Assurance Limited.

 
Page 7